Hematopoietic stem cell expansion and generation: The ways to make a breakthrough

Blood Research

Volumn 50, Issue 4, 2015, Pages 194-203

  Park, Bokyung ^a   Yoo, Keon Hee ^b,c   Kim, Changsung ^a  

^a Sejong University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

Blood generation; HLA; HSC expansion; HSCT; Stem cell

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; DECITABINE; DNA METHYLTRANSFERASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 11; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 9; OCTAMER TRANSCRIPTION FACTOR 4; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; VALPROIC ACID; VASCULOTROPIN;

BONE MARROW APLASIA; CELL DIFFERENTIATION; COLONY FORMING UNIT; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; MESENCHYMAL STROMA CELL; NONHUMAN; ONCOGENE C MYC; PLURIPOTENT STEM CELL; REVIEW; STEM CELL EXPANSION; TOTIPOTENT STEM CELL;

EID: 84951150142     PISSN: 2287979X     EISSN: 22880011     Source Type: Journal    
DOI: 10.5045/br.2015.50.4.194     Document Type: Review

References (73)

1. Meuwissen HJ, Gatti RA, Terasaki PI, Hong R, Good RA.Treatment of lymphopenic hypogammaglobulinemia and bonemarrowaplasia by transplantation of allogeneic marrow. Crucialrole of histocompatiility matching. N Engl J Med 1969;281:691-7.
2. Oran B, Shpall E. Umbilical cord blood transplantation: a maturingtechnology. Hematology Am Soc Hematol Educ Program 2012;2012:215-22.
3. Pineault N, Abu-Khader A. Advances in umbilical cord blood stemcell expansion and clinical translation. Exp Hematol 2015;43:498-513.
4. Scaradavou A, Brunstein CG, Eapen M, et al. Double unit graftssuccessfully extend the application of umbilical cord blood transplantationin adults with acute leukemia. Blood 2013;121:752-8.
5. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2partially HLA-matched umbilical cord blood units to enhanceengraftment in adults with hematologic malignancy. Blood2005;105:1343-7.
6. Pasquini MC, Zhu X. Current uses and outcomes of hematopoieticstem cell transplantation: 2014 CIBMTR summary slides. Minneapolis,MN: Center for International Blood and MarrowTransplantation Research (CIBMTR), 2015.(Accessed October11, 2015, at https://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx)
7. de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftmentwith ex vivo mesenchymal-cell coculture. N Engl J Med2012;367:2305-15.
8. Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord bloodexpansion with nicotinamide provides long-term multilineageengraftment. J Clin Invest 2014;124:3121-8.
9. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL,Bernstein ID. Notch-mediated expansion of human cord bloodprogenitor cells capable of rapid myeloid reconstitution. Nat Med2010;16:232-6.
10. Wagner JE, Brunstein C, McKenna D, et al. Acceleration ofumbilical cord blood (UCB) stem engraftment: Results of a phaseI clinical trial with stemregenin-1 (SR1) expansion culture. BiolBlood Marrow Transplant 2015;21:S48-9.
11. Silva LC, Ortigosa LC, Benard G. Anti-TNF-a agents in the treatmentof immune-mediated inflammatory diseases: mechanismsof action and pitfalls. Immunotherapy 2010;2:817-33.
12. Elman JS, Li M, Wang F, Gimble JM, Parekkadan B. A comparisonof adipose and bone marrow-derived mesenchymal stromal cellsecreted factors in the treatment of systemic inflammation. JInflamm (Lond) 2014;11:1.
13. Reardon S, Cyranoski D. Japan stem-cell trial stirs envy. Nature2014;513:287-8.
14. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcomeafter unrelated marrow transplantation by comprehensivematching of HLA class I and II alleles in the donor and recipient.Blood 1998;92:3515-20.
15. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplantsfrom unrelated donors for patients with chronic myeloidleukemia. N Engl J Med 1998;338:962-8.
16. de Lima M, McMannis J, Gee A, et al. Transplantation of ex vivoexpanded cord blood cells using the copper chelator tetraethylenepentamine:a phase I/II clinical trial. Bone Marrow Transplant2008;41:771-8.
17. Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, Bolton EM.Generating an iPSC bank for HLA-matched tissue transplantationbased on known donor and recipient HLA types. Cell Stem Cell2012;11:147-52.
18. Wagner JE Jr EM, Carter S, Wang Y, et al. One-unit versustwo-unit cord-blood transplantation for hematologic cancers. NEngl J Med 2014;371:1685-94.
19. Weidner CI, Walenda T, Lin Q, et al. Hematopoietic stem andprogenitor cells acquire distinct DNA-hypermethylation duringin vitro culture. Sci Rep 2013;3:3372.
20. Xie J, Zhang C. Ex vivo expansion of hematopoietic stem cells. SciChina Life Sci 2015;58:839-53.
21. Chaurasia P, Gajzer DC, Schaniel C, D'Souza S, Hoffman R.Epigenetic reprogramming induces the expansion of cord bloodstem cells. J Clin Invest 2014;124:2378-95.
22. Young JC, Wu S, Hansteen G, et al. Inhibitors of histone deacetylasespromote hematopoietic stem cell self-renewal. Cytotherapy2004;6:328-36.
23. Araki H, Yoshinaga K, Boccuni P, Zhao Y, Hoffman R, MahmudN. Chromatin-modifying agents permit human hematopoieticstem cells to undergo multiple cell divisions while retaining theirrepopulating potential. Blood 2007;109:3570-8.
24. Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1inhibitor, inhibits differentiation and facilitates expansion ofhematopoietic progenitor cells with enhanced bone marrowhoming and engraftment. Exp Hematol 2012;40:342-55.e1.
25. Lang J, Weiss N, Freed BM, Torres RM, Pelanda R. Generation ofhematopoietic humanized mice in the newborn BALB/c-Rag2nullIl2rγnull mouse model: a multivariable optimization approach.Clin Immunol 2011;140:102-16.
26. Berges BK, Wheat WH, Palmer BE, Connick E, Akkina R. HIV-1infection and CD4 T cell depletion in the humanized Rag2-/-gammac-/- (RAG-hu) mouse model. Retrovirology 2006;3:76.
27. Matsuoka Y, Sumide K, Kawamura H, et al. Human cordblood-derived primitive CD34-negative hematopoietic stem cells(HSCs) are myeloid-biased long-term repopulating HSCs. BloodCancer J 2015;5:e290.
28. Tanner A, Taylor SE, Decottignies W, Berges BK. Humanizedmice as a model to study human hematopoietic stem celltransplantation. Stem Cells Dev 2014;23:76-82.
29. Brehm MA, Shultz LD, Luban J, Greiner DL. Overcoming currentlimitations in humanized mouse research. J Infect Dis 2013;208(Suppl 2):S125-30.
30. Lee K, Kwon DN, Ezashi T, et al. Engraftment of human iPS cellsand allogeneic porcine cells into pigs with inactivated RAG2 andaccompanying severe combined immunodeficiency. Proc NatlAcad Sci U S A 2014;111:7260-5.
31. Larochelle A, Vormoor J, Hanenberg H, et al. Identification ofprimitive human hematopoietic cells capable of repopulatingNOD/SCID mouse bone marrow: implications for gene therapy.Nat Med 1996;2:1329-37.
32. Ishii M, Matsuoka Y, Sasaki Y, et al. Development of a highresolutionpurification method for precise functional characterizationof primitive human cord blood-derived CD34-negativeSCID-repopulating cells. Exp Hematol 2011;39:203-13.e1.
33. Lu R, Neff NF, Quake SR, Weissman IL. Tracking single hematopoieticstem cells in vivo using high-throughput sequencing inconjunction with viral genetic barcoding. Nat Biotechnol2011;29:928-33.
34. Kim C. iPSC technology-Powerful hand for disease modeling andtherapeutic screen. BMB Rep 2015;48:256-65.
35. Kim H, Kim JS. A guide to genome engineering with programmablenucleases. Nat Rev Genet 2014;15:321-34.
36. Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK. CRISPRRNA-guided activation of endogenous human genes. NatMethods 2013;10:977-9.
37. Kim C. Disease modeling and cell based therapy with iPSC: futuretherapeutic option with fast and safe application. Blood Res2014;49:7-14.
38. Ding Q, Lee YK, Schaefer EA, et al. A TALEN genome-editingsystem for generating human stem cell-based disease models. CellStem Cell 2013;12:238-51.
39. Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol2013;31:397-405.
40. Joung JK, Sander JD. TALENs: a widely applicable technology fortargeted genome editing. Nat Rev Mol Cell Biol 2013;14:49-55.
41. Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stemcell trials for macular degeneration: a preliminary report. Lancet2012;379:713-20.
42. Song WK, Park KM, Kim HJ, et al. Treatment of macular degenerationusing embryonic stem cell-derived retinal pigmentepithelium: preliminary results in Asian patients. Stem CellReports 2015;4:860-72.
43. Takahashi K, Yamanaka S. Induction of pluripotent stem cellsfrom mouse embryonic and adult fibroblast cultures by definedfactors. Cell 2006;126:663-76.
44. Kanemura H, Go MJ, Shikamura M, et al. Tumorigenicity studiesof induced pluripotent stem cell (iPSC)-derived retinal pigmentepithelium (RPE) for the treatment of age-related maculardegeneration. PLoS One 2014;9:e85336.
45. Schlaeger TM, Daheron L, Brickler TR, et al. A comparison ofnon-integrating reprogramming methods. Nat Biotechnol2015;33:58-63.
46. Geron Corporation. World's first clinical trial of humanembryonic stem cell therapy cleared. Regen Med 2009;4:161.
47. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cellanemia mouse model with iPS cells generated from autologousskin. Science 2007;318:1920-3.
48. Wang L, Li L, Menendez P, Cerdan C, Bhatia M. Humanembryonic stem cells maintained in the absence of mouseembryonic fibroblasts or conditioned media are capable ofhematopoietic development. Blood 2005;105:4598-603.
49. Woll PS, Grzywacz B, Tian X, et al. Human embryonic stem cellsdifferentiate into a homogeneous population of natural killer cellswith potent in vivo antitumor activity. Blood 2009;113:6094-101.
50. Galic Z, Kitchen SG, Kacena A, et al. T lineage differentiation fromhuman embryonic stem cells. Proc Natl Acad Sci U S A 2006;103:11742-7.
51. Carpenter L, Malladi R, Yang CT, et al. Human inducedpluripotent stem cells are capable of B-cell lymphopoiesis. Blood2011;117:4008-11.
52. Knorr DA, Ni Z, Hermanson D, et al. Clinical-scale derivation ofnatural killer cells from human pluripotent stem cells for cancertherapy. Stem Cells Transl Med 2013;2:274-83.
53. Ledran MH, Krassowska A, Armstrong L, et al. Efficienthematopoietic differentiation of human embryonic stem cells onstromal cells derived from hematopoietic niches. Cell Stem Cell2008;3:85-98.
54. Gori JL, Butler JM, Chan YY, et al. Vascular niche promoteshematopoietic multipotent progenitor formation from pluripotentstem cells. J Clin Invest 2015;125:1243-54.
55. Ramos-Mejía V, Navarro-Montero O, Ayllón V, et al. HOXA9promotes hematopoietic commitment of human embryonic stemcells. Blood 2014;124:3065-75.
56. Real PJ, Ligero G, Ayllon V, et al. SCL/TAL1 regulates hematopoieticspecification from human embryonic stem cells. MolTher 2012;20:1443-53.
57. Doulatov S, Vo LT, Chou SS, et al. Induction of multipotentialhematopoietic progenitors from human pluripotent stem cells viarespecification of lineage-restricted precursors. Cell Stem Cell2013;13:459-70.
58. Ran D, Shia WJ, Lo MC, et al. RUNX1a enhances hematopoieticlineage commitment from human embryonic stem cells andinducible pluripotent stem cells. Blood 2013;121:2882-90.
59. Amabile G, Welner RS, Nombela-Arrieta C, et al. In vivogeneration of transplantable human hematopoietic cells frominduced pluripotent stem cells. Blood 2013;121:1255-64.
60. Suzuki N, Yamazaki S, Yamaguchi T, et al. Generation ofengraftable hematopoietic stem cells from induced pluripotentstem cells by way of teratoma formation. Mol Ther 2013;21:1424-31.
61. Szabo E, Rampalli S, Risueño RM, et al. Direct conversion ofhuman fibroblasts to multilineage blood progenitors. Nature2010;468:521-6.
62. Sandler VM, Lis R, Liu Y, et al. Reprogramming human endothelialcells to haematopoietic cells requires vascular induction.Nature 2014;511:312-8.
63. Riddell J, Gazit R, Garrison BS, et al. Reprogramming committedmurine blood cells to induced hematopoietic stem cells withdefined factors. Cell 2014;157:549-64.
64. Batta K, Florkowska M, Kouskoff V, Lacaud G. Direct reprogrammingof murine fibroblasts to hematopoietic progenitor cells.Cell Rep 2014;9:1871-84.
65. Lu SJ, Li F, Yin H, et al. Platelets generated from human embryonicstem cells are functional in vitro and in the microcirculation ofliving mice. Cell Res 2011;21:530-45.
66. Nakamura S, Takayama N, Hirata S, et al. Expandable megakaryocytecell lines enable clinically applicable generation ofplatelets from human induced pluripotent stem cells. Cell StemCell 2014;14:535-48.
67. Kennedy M, Awong G, Sturgeon CM, et al. T lymphocyte potentialmarks the emergence of definitive hematopoietic progenitors inhuman pluripotent stem cell differentiation cultures. Cell Rep2012;2:1722-35.
68. Liu Z, Lu SJ, Lu Y, et al. Transdifferentiation of Human HairFollicle Mesenchymal Stem Cells into Red Blood Cells by OCT4.Stem Cells Int 2015;2015:389628.
69. Vodyanik MA, Bork JA, Thomson JA, Slukvin II. Humanembryonic stem cell-derived CD34+ cells: efficient production inthe coculture with OP9 stromal cells and analysis of lymphohematopoieticpotential. Blood 2005;105:617-26.
70. Wada H, Kojo S, Kusama C, et al. Successful differentiation to Tcells, but unsuccessful B-cell generation, from B-cell-derivedinduced pluripotent stem cells. Int Immunol 2011;23:65-74.
71. Sturgeon CM, Ditadi A, Awong G, Kennedy M, Keller G. Wntsignaling controls the specification of definitive and primitivehematopoiesis from human pluripotent stem cells. Nat Biotechnol2014;32:554-61.
72. Chen U. Do we have a workable clinical protocol for differentiatinglympho-hematopoietic stem cells from the source ofembryonic stem cells and induced pluripotent stem cells inculture? Scand J Immunol 2014;80:247-9.
73. Gori JL, Chandrasekaran D, Kowalski JP, et al. Efficient generation,purification, and expansion of CD34(+) hematopoieticprogenitor cells from nonhuman primate-induced pluripotentstem cells. Blood 2012;120:e35-44.